Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study
作者: David E. CohnMichael W. SillJoan L. WalkerDavid O'MalleyChrista I. NagelTeresa L. RutledgeWilliam BradleyDebra L. RichardsonKatherine M. MoxleyCarol Aghajanian
作者单位: 1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ohio State University College of Medicine, Columbus, OH, United States
2NRG Oncology/Gynecologic Oncology Group, Statistics & Data Management, Roswell Park Cancer Institute, Buffalo, NY, United States
3Department of OB/GYN, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States
4Dept of Gynecologic Oncology, Case Western Reserve University, Cleveland, OH 44106, United States
5Division of Gyn/Oncology, University of New Mexico, Albuquerque, NM 87131, United States
6Dept. of OB/GYN, Medical College of Wisconsin, Milwaukee, WI 53226, United States
7Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 95390-9032, United States
8Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 120021, United States
刊名: Gynecologic Oncology, 2017, Vol.146 (3), pp.477-483
来源数据库: Elsevier Journal
DOI: 10.1016/j.ygyno.2017.07.135
关键词: Oncolytic virusRecurrent ovarian cancerPaclitaxel
原始语种摘要: Abstract(#br)Objective(#br)To assess whether the addition of oncolytic reovirus (Reolysin®) to weekly paclitaxel prolonged progression-free survival (PFS) in the treatment of women with recurrent or persistent ovarian, tubal or primary peritoneal cancer.(#br)Patients and methods(#br)Patients with recurrent or persistent epithelial ovarian, tubal, or peritoneal carcinoma, measurable or detectable disease, and three or fewer prior regimens were randomly assigned to paclitaxel (80mg/m 2 intravenously days 1, 8, and 15 every 4weeks) or the combination of paclitaxel (80mg/m 2 intravenously days 1, 8, and 15) plus reovirus 3×10 10 TCID 50 /day intravenously on days 1–5, both every...
全文获取路径: Elsevier  (合作)
影响因子:3.929 (2012)

  • tubal 管的
  • weekly 每周的
  • oncolytic 肿瘤消解
  • recurrent 循环的
  • ovarian 卵巢的
  • peritoneal 腹膜的
  • reovirus 呼肠孤病毒
  • cancer 癌症
  • versus 
  • phase 相位